Clinical trials
Graft vs Host Disease trials in Russia
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
14 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2007 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 3 |
| 2018 | 1 |
| 2020 | 2 |
| 2021 | 1 |
| 2023 | 1 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 9 |
| Active, not recruiting | 3 |
| Recruiting | 1 |
| Unknown status | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| St. Petersburg State Pavlov Medical University | 4 |
| Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 3 |
| Novartis Pharmaceuticals | 3 |
| Incyte Corporation | 1 |
| National Research Center for Hematology, Russia | 1 |
| Pharmacyclics LLC. | 1 |
| Pharmacyclics Switzerland GmbH | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Graft vs Host Disease | 14 |
| Leukemia, Myeloid, Acute | 6 |
| Bronchiolitis Obliterans Syndrome | 5 |
| Myelodysplastic Syndromes | 4 |
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 |
| Lymphoma | 2 |
| Opportunistic Infections | 2 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 |
| Bone Marrow Failure Disorders | 1 |
| Leukemia | 1 |
Trials
Showing 26 to 14 of 14. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.